Luo Yunxiu

Deputy Chief Physician

Introduction of the expert

Luo Yunxiu, Deputy Director of Radiotherapy Ward 3, deputy chief physician. Graduated from Central South University, MD, PI. Received systematic training in radiotherapy specialties at renowned domestic oncology specialty hospitals in Chengdu, Beijing and Guangzhou.

Medical specialty

Specializes in head and neck cancer (cranial/nasopharyngeal/oropharyngeal/hypopharyngeal/laryngeal/parotid/sinus/esophageal, etc.); breast cancer; digestive system tumors (liver/pancreas/gastrointestinal/pancreatic/gallbladder, etc.); genitourinary (cervical, prostate, endometrial and renal) tumors; childrens tumors, soft-tissue sarcomas, thoracic tumors, and rare tumors; specializes in the treatment of difficult, complex and intractable tumors through the integration of multi-modality advanced radiotherapy; and has rich experience in prevention & diagnosis and treatment of radiotherapy complications of tumors.

Direction of scientific research

Generation and development of malignant tumors, radiation therapy and comprehensive treatment of tumors, multimodal radiotherapy for complex and refractory tumors.

Academic position

I. Member of the Second Committee of Tumor Support Therapy Professional Committee of Chinese Anti-Cancer Association

II. Member of the Third Session of Radiotherapy Equipment Technology Branch of China Medical Equipment Association

III. Member of the Sixth Radiation Tumor Professional Committee of Hainan Medical Association

IV. Member of Lung Cancer Professional Committee of Hainan Cancer Prevention and Treatment Association

V. Vice Chairman of the MDT Professional Committee of Hainan Cancer Prevention and Treatment Association

VI. Standing member of the Fertility Preservation Professional Committee of the Maternal and Child Health Association of Hainan Province

Papers and works

I. Proteomics analysis of G protein-coupled receptor kinase 4-inhibited cellular growth of HEK293 cells. J Proteomics. 2019; 207:103445。

II. The role of radiotherapy for pancreatic malignancies: a population-based analysis of the SEER database,Clin Transl Oncol,2021,7。

III. Role of CD5L and SRD5A2 as Prognostic Biomarkers for Hepatocellular Carcinoma,Int J Gen Med,2021,14: 9247—9260。

IV. Myoepithelial carcinoma of major salivary glands: Analysis ofpopulation-based clinicopathologic and prognostic features,Translational oncology  20 (2022) 101410。